Arrowhead Pharmaceuticals’ (ARWR) Buy Rating Reiterated at HC Wainwright

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $120.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 104.09% from the company’s previous close.

ARWR has been the topic of several other reports. Morgan Stanley raised their target price on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. B. Riley Financial raised their target price on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Citigroup assumed coverage on Arrowhead Pharmaceuticals in a report on Tuesday, September 8th. They set a “buy” rating and a $108.00 target price on the stock. Leerink Partners raised their target price on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a report on Wednesday, June 17th. Finally, JPMorgan Chase & Co. raised their target price on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $98.31.

Arrowhead Pharmaceuticals Stock Up 0.7%

ARWR traded up $0.43 during trading on Thursday, reaching $58.80. 566,891 shares of the stock traded hands, compared to its average volume of 2,283,311. The stock has a market cap of $8.28 billion, a price-to-earnings ratio of -26.12 and a beta of 1.29. Arrowhead Pharmaceuticals has a fifty-two week low of $36.57 and a fifty-two week high of $95.49. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. The stock’s 50-day simple moving average is $76.71 and its two-hundred day simple moving average is $75.99.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. During the same period in the previous year, the business posted ($1.26) EPS. Arrowhead Pharmaceuticals’s revenue for the quarter was up 171.0% on a year-over-year basis. As a group, equities research analysts expect that Arrowhead Pharmaceuticals will post -3.62 EPS for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, Director Adeoye Olukotun sold 2,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares in the company, valued at $9,730,370.70. The trade was a 9.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ARWR. Optiver Holding B.V. increased its stake in shares of Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares during the period. Versant Capital Management Inc increased its stake in shares of Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares during the period. Carolina Wealth Advisors LLC increased its stake in shares of Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 154 shares during the period. Persistent Asset Partners Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth about $39,000. Finally, First Horizon Corp increased its stake in shares of Arrowhead Pharmaceuticals by 36.3% in the first quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 174 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Key Stories Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Positive ARO-MAPT results: Interim Phase 1/2a data showed up to a 73% reduction in tau, a protein associated with Alzheimer’s disease, with reductions described as deep and durable in healthy volunteers. The company said the results provide the first clinical validation of its TRiM platform’s ability to deliver siRNA across the blood-brain barrier and reduce a target gene in the brain. Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data
• Positive Sentiment: Alzheimer’s program strengthens the pipeline: The reported ability to cross the blood-brain barrier could support ARO-MAPT and other programs using Arrowhead’s TRiM CNS delivery platform. Coverage highlighted the potential significance of the early-stage data, although the study remains investigational and was conducted in healthy volunteers. Arrowhead Reports Positive Phase 1/2a Data for Alzheimer’s Candidate ARO-MAPT
• Positive Sentiment: Analysts reaffirm bullish views: Chardan Capital reiterated its “buy” rating and set a $115 price target, while HC Wainwright also reaffirmed “buy” with a $120 target. Both targets imply substantial upside from recent trading levels, providing additional support for investor sentiment.
• Neutral Sentiment: Important clinical caveat: The ARO-MAPT findings are interim Phase 1/2a results and primarily demonstrate biomarker reduction and delivery, not yet proof that the therapy improves cognition or slows Alzheimer’s disease. Further clinical testing will be needed to establish efficacy and safety. Arrowhead Discusses ARO-MAPT Interim Results and TRiM CNS Delivery
• Neutral Sentiment: Some coverage noted differing analyst views on healthcare stocks, including Arrowhead, indicating that valuation and execution risks remain despite the favorable ARO-MAPT update.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.